uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study
Department of Urology, University Hospital Maastricht, The Netherlands.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Obstetrics and Gynaecology. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Department of Urology, Hopital Saint Louis, Paris, France.
Department of Urology, Johannes Gutenberg University Medical School, Mainz, Germany.
Show others and affiliations
2007 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 52, no 1, 221-229 p.Article in journal (Refereed) Published
Abstract [en]

Objectives: To investigate efficacy, safety, and impact on quality of sleep of desmopressin in the treatment of nocturia. Methods: Adults aged >= 18 yr with nocturia (>= 2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period. Patients should show sufficient response during the dose-titration period (>= 20% reduction in nocturnal diuresis) and a return of nocturnal diuresis to >= 80% of baseline levels during washout. Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo. Results: 127 patients were randomised to either desmopressin (n = 61) or placebo (n = 66). Twenty (33%) desmopressin-treated patients compared with seven (11%) placebo-treated patients showed a clinical response, defined as a >= 50% reduction in the number of nocturnal voids compared with baseline (p = 0.0014). Compared with placebo, desmopressin resulted in a significant reduction in the mean number of nocturnal voids (39% reduction with desmopressin vs. 15% with placebo; absolute difference -0.84, p < 0.0001) and duration of the first sleep period (prolonged by 108 min with desmopressin vs. 41 min with placebo; p < 0.0001). Quality of sleep was also improved with clesmopressin versus placebo (statistically significant for one of the two parameters evaluated). Adverse events were mainly mild. Conclusions: Oral clesmopressin tablets provide an effective and well-tolerated treatment for nocturia. Compared with placebo, nocturnal voiding frequency is reduced, duration of the first sleep period is increased, and sleep quality may be improved. (c) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Place, publisher, year, edition, pages
2007. Vol. 52, no 1, 221-229 p.
Keyword [en]
antidiuresis, desmopressin, double-blind, efficacy, nocturia, safety, sleep
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-262494DOI: 10.1016/j.eururo.2007.01.027ISI: 000247281400035PubMedID: 17280773OAI: oai:DiVA.org:uu-262494DiVA: diva2:854046
Available from: 2015-09-15 Created: 2015-09-15 Last updated: 2015-09-15

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Rezapour, Masoumeh
By organisation
Obstetrics and Gynaecology
In the same journal
European Urology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 168 hits
ReferencesLink to record
Permanent link

Direct link